Until recently, the therapeutic use of non-cosmetic Botox (botulinum toxin) for adult upper extremity spasticity was considered off-label use. The U.S. Food and Drug Administration (FDA) has now approved Botox to treat spasticity in the upper extremity flexor muscles in adults.
Spasticity is common after stroke, traumatic brain injury, or the progression of multiple sclerosis. Spasticity is defined as:
“a motor disorder characterized by a velocity-dependent increase in tonic stretch reflexes (muscle tone) with exaggerated tendon jerks, resulting from hyper-excitability of the stretch reflex as one component of the upper motor neuron syndrome.”
Spasticity often creates problems with mobility, self-care, and function. The spastic muscles can become stiff. Associated joints can be affected by lack decreased range-of-motion with contractures forming. Read more »
*This blog post was originally published at Suture for a Living*